Program
V118C
A development code. Also written as “V118C (Stage 1)” and “V118C (Stage 2)”.
Its studies are mostly in Pneumococcal Infections, led by Merck.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 21 open or running | phase 1since Sep 20, 2024 | Sep 20, 2024 | Oct 24, 2028phase 1 · NCT07300267 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 20, 2024First study: phase 1 study in HealthyFirst studyNCT06611033 · 65 enrolled · United States
- Dec 10, 2025Phase 1 study in Pneumococcal InfectionsNCT07300267 · 210 planned · United States
Ahead
- Oct 24, 2028Primary completion: phase 1 study in Pneumococcal InfectionsNCT07300267
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07300267Pneumococcal Infections · United States | 1 | Recruiting | Oct 24, 2028 | 210 |
| NCT06611033Healthy · United States | 1 | Completed | Jan 9, 2026 | 65 |
How it is read
Names in the registry
- “V118C (Stage 1)”, 1 entry
- “V118C (Stage 2)”, 1 entry
- “V118C”, 1 entry
Codes read as this program: V118C.
Conditions, from the studies’ own filings
- Pneumococcal Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.